Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-25T06:26:29.106Z Has data issue: false hasContentIssue false
  • English
  • Français

“Discontinuous” Thioproperazine: A Controlled Trial in Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

J. Moffat  and
E. C. MacLeod
J. Moffat
Affiliation:
Glasgow Royal Mental Hospital
E. C. MacLeod
Affiliation:
Department of Psychological Medicine, Southern General Hospital, Glasgow
Get access Rights & Permissions [Opens in a new window]

Extract

It became apparent soon after the introduction of chlorpromazine and reserpine that these drugs were capable both of influencing psychoses and of producing neurological disturbances closely resembling those seen in post-encephalitic Parkinsonism. In classifying drugs with these effects as “neuroleptics” Delay et al. (2) indicated that they considered the two actions to be inseparable thus implying that both resulted from common or closely related neurophysiological changes. On this basis it seemed likely that drugs which more readily produced these neurological disturbances would prove more effective in psychotic illness. It also seemed possible that there might be therapeutic value in the deliberate provocation of such disturbances, as was first advocated by Fleugel (6). The theoretical issues involved were referred to in a previous paper (MacLeod and Moffat (8)).

Type
Research Article
Information
The British Journal of Psychiatry , Volume 110 , Issue 469 , November 1964 , pp. 851 - 854
Copyright
Copyright © Royal College of Psychiatrists, 1964 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Baker, A. A., and Thorpe, J. G. (1956). “Some simple measures of schizophrenic deterioration.” J. Ment. Sci., 102, 838–846.CrossRefGoogle Scholar
2. Delay, J., and Deniker, P. (1955). “Hibernothérapies et cures neuroleptiques en psychiatrie.” Acad. Nat. de Médecine 139, Nos. 7–8, 145–147.Google Scholar
3. Delay, J., and Deniker, P., Ropert, R., Beek, N., Barande, R., and Eurieult, M. (1959a). “Syndromes neurologiques experimentaux et thérapeutique psychiatrique. 1. Effets neurologiques d'un nouveau neuroleptique majeur, le 7843 R.P.” Presse Medicale, 67, 123–126.Google Scholar
4. Delay, J., and Deniker, P., Ropert, R., Beek, N., Barande, R., and Eurieult, M. (1959b). “Effets psychiques et thérapeutiques d'un nouveau neuroleptique majeur, le 7843 R.P. Etude polygraphique.” Ibid., 67, 201–207.Google Scholar
5. Denham, J., and Carrick, D. J. E. L. (1961). “Therapeutic value of thioproperazine and the importance of the associated neurological disbances.” J. Ment. Sci., 107, 326–345.CrossRefGoogle Scholar
6. Fleugel, F. (1956). “Thérapeutique par médication neuroleptique obtenue en réalisant systématiquement des états parkinsoniformes.” Encéphale, 790–792.Google Scholar
7. Lingjaerde, O. (1963). “Clinical experiences with thioproperazine in chronic schizophrenia, psychotic excitation and senile agitation.” Psychopharmacologica, 4, 281–293.CrossRefGoogle Scholar
8. MacLeod, E. C., and Moffat, J. (1963). “‘Continuous' thioproperazine. A controlled trial in chronic schizophrenia.” Brit. J. Psychiat., 109, 531–535.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.